Compare Global X FTSE Southeast Asia ETF (ASEA) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Citius Pharmaceuticals Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.47, while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | CTXR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $21.53 | $1.82 |
52-Week Low | $16.86 | $0.48 |
Market Cap | — | $20.01M |
Enterprise Value | — | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA trades at $21.53, up 1.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows uniform support and resistance at $21. Key financial ratios are unavailable, but a dividend of $0.41 is scheduled for July 2026. Recent business developments and earnings data are not provided, limiting fundamental assessment.
The outlook is cautiously optimistic due to strong technical momentum, though the absence of current financial metrics and news increases uncertainty. Investment opportunity hinges on upcoming financial disclosures, while risks include data gaps and market volatility. Investors should await earnings reports for clearer valuation insights.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
